{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:24:59Z","timestamp":1786980299863,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007827","name":"American College of Gastroenterology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007827","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology Clinics of North America"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.gtc.2026.05.007","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:41:36Z","timestamp":1782333696000},"page":"473-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease"],"prefix":"10.1016","volume":"55","author":[{"given":"Winnie Y.","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira L.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.gtc.2026.05.007_bib1","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","article-title":"Trends in U.S. burden of Clostridioides difficile infection and outcomes","volume":"382","author":"Guh","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.gtc.2026.05.007_bib2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa1408913","article-title":"Burden of Clostridium difficile infection in the United States","volume":"372","author":"Lessa","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"10.1016\/j.gtc.2026.05.007_bib4","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/ajg.2016.187","article-title":"Recurrence of clostridium difficile infection in patients with inflammatory bowel disease: the RECIDIVISM study","volume":"111","author":"Razik","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.007_bib5","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2017.04.044","article-title":"Higher incidence of Clostridium difficile infection among individuals with inflammatory bowel disease","volume":"153","author":"Singh","year":"2017","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib6","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1038\/ajg.2009.4","article-title":"The vexed relationship between clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission","volume":"104","author":"Clayton","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gtc.2026.05.007_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.anaerobe.2024.102878","article-title":"Incidence of public health surveillance-reported Clostridioides difficile infections in thirteen countries worldwide: a narrative review","volume":"88","author":"Angulo","year":"2024","journal-title":"Anaerobe"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.007_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cgh.2006.12.028","article-title":"Impact of Clostridium difficile on inflammatory bowel disease","volume":"5","author":"Issa","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.007_bib9","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/j.1572-0241.2007.01780.x","article-title":"A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients","volume":"103","author":"Nguyen","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.007_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cgh.2006.12.027","article-title":"Incidence of Clostridium difficile infection in inflammatory bowel disease","volume":"5","author":"Rodemann","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.007_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.01290-24","article-title":"Global, regional, and national burdens of Clostridioides difficile infection over recent decades: a trend analysis informed by the global Burden of disease study","volume":"13","author":"Zhou","year":"2025","journal-title":"Microbiol Spectr"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.007_bib12","first-page":"24","article-title":"Global patterns of Clostridioides difficile infection in patients with inflammatory bowel disease: a systematic review and meta-analysis of prevalence, epidemiology, and risk factors","volume":"7","author":"Amakye","year":"2025","journal-title":"Crohns Colitis 360"},{"issue":"12","key":"10.1016\/j.gtc.2026.05.007_bib13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/j.1365-2036.2011.04661.x","article-title":"Increased health burden associated with Clostridium difficile diarrhoea in patients with inflammatory bowel disease","volume":"33","author":"Jen","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"11\u201312","key":"10.1016\/j.gtc.2026.05.007_bib14","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/apt.12073","article-title":"Impact of Clostridium difficile colitis on 5-year health outcomes in patients with ulcerative colitis","volume":"36","author":"Murthy","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.007_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/gut.2007.128231","article-title":"Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease","volume":"57","author":"Ananthakrishnan","year":"2008","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib16","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1053\/j.gastro.2007.03.034","article-title":"A nonsynonymous SNP in ATG16L1 predisposes to ileal crohn\u2019s disease and is independent of CARD15 and IBD5","volume":"132","author":"Prescott","year":"2007","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib17","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2010.07.006","article-title":"ATG16L1 and NOD2 interact in an autophagy-dependent antibacterial pathway implicated in crohn\u2019s disease pathogenesis","volume":"139","author":"Homer","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.007_bib18","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1053\/j.gastro.2010.12.002","article-title":"Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases","volume":"140","author":"Hovhannisyan","year":"2011","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.gtc.2026.05.007_bib19","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1053\/j.gastro.2005.03.043","article-title":"Peripheral and intestinal regulatory CD4+CD25high T cells in inflammatory bowel disease","volume":"128","author":"Maul","year":"2005","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.gtc.2026.05.007_bib20","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/MIB.0b013e318281f5a3","article-title":"Induced and natural regulatory T cells in the development of inflammatory bowel disease","volume":"19","author":"Mayne","year":"2013","journal-title":"Inflamm Bowel Dis"},{"issue":"43","key":"10.1016\/j.gtc.2026.05.007_bib21","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.3748\/wjg.v27.i43.7402","article-title":"Antimicrobial peptides and the gut microbiome in inflammatory bowel disease","volume":"27","author":"Gubatan","year":"2021","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.007_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00021-17","article-title":"Understanding clostridium difficile colonization","volume":"31","author":"Crobach","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.007_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00567-24","article-title":"Genetic insight into the relationship between inflammatory bowel disease and Clostridioides difficile infection","volume":"9","author":"Cushing-Damm","year":"2024","journal-title":"mSphere"},{"issue":"Supplement_3","key":"10.1016\/j.gtc.2026.05.007_bib24","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1093\/infdis\/jiaa408","article-title":"Mechanisms of colonization resistance against Clostridioides difficile","volume":"223","author":"Pike","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.gtc.2026.05.007_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.72801","article-title":"Multi-omics investigation of Clostridioides difficile-colonized patients reveals pathogen and commensal correlates of C. difficile pathogenesis","volume":"11","author":"Fishbein","year":"2022","journal-title":"eLife"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.007_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/microorganisms9020371","article-title":"Contribution of inhibitory metabolites and competition for nutrients to colonization resistance against clostridioides difficile by commensal clostridium","volume":"9","author":"Reed","year":"2021","journal-title":"Microorganisms"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.007_bib27","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41591-020-0764-0","article-title":"Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota","volume":"26","author":"Nagao-Kitamoto","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.gtc.2026.05.007_bib28","first-page":"1183","article-title":"Clostridium difficile infection and inflammatory bowel disease: a marker for disease extent?","volume":"57","author":"Powell","year":"2008","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/jpids\/piaa150","article-title":"Review and commentary on the importance of bile acids in the life cycle of Clostridioides difficile in children and adults","volume":"10","author":"Faden","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.007_bib30","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jpeds.2008.12.039","article-title":"Impact of clostridium difficile infection on pediatric inflammatory bowel disease","volume":"154","author":"Pascarella","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.gtc.2026.05.007_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17562848251318292","article-title":"Higher disease activity of inflammatory bowel disease predisposes to Clostridioides difficile infection","volume":"18","author":"Vitikainen","year":"2025","journal-title":"Therapeut Adv Gastroenterol"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.007_bib32","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1111\/jgh.16720","article-title":"Antibiotic use and risk of Clostridioides difficile infection in patients with inflammatory bowel disease","volume":"39","author":"Bejcek","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.007_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/ibd\/izac165","article-title":"Prevalence of clostridioides difficile infection after ileal pouch-anal anastomosis in patients with chronic antibiotic-dependent pouchitis and crohn\u2019s-like disease of the pouch","volume":"29","author":"Shore","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.gtc.2026.05.007_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/ecco-jcc\/jjaf103","article-title":"ECCO topical review on pouch disorders","volume":"19","author":"Kayal","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.007_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2023.10.015","article-title":"AGA clinical practice guideline on the management of pouchitis and inflammatory pouch disorders","volume":"166","author":"Barnes","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.007_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cgh.2016.10.024","article-title":"Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the clinical practice updates committee of the AGA institute","volume":"15","author":"Khanna","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib37","first-page":"313","article-title":"Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease","volume":"8","author":"Shakir","year":"2012","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gtc.2026.05.007_bib38","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/ibd\/izad238","article-title":"Dysregulated immunity to Clostridioides difficile in IBD patients without a history of recognized infection","volume":"30","author":"Cook","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.007_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01904-22","article-title":"Intestinal inflammation reversibly alters the microbiota to drive susceptibility to Clostridioides difficile colonization in a mouse model of colitis","volume":"13","author":"Barron","year":"2022","journal-title":"mBio"},{"issue":"6","key":"10.1016\/j.gtc.2026.05.007_bib40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib41","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.gtc.2026.05.007_bib42","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.cgh.2008.02.021","article-title":"Clostridium difficile infection in patients with ileal pouch\u2013anal anastomosis","volume":"6","author":"Shen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.007_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MCG.0b013e3181a7481b","article-title":"Clostridium difficile-associated small bowel enteritis after total proctocolectomy in a crohn\u2019s disease patient","volume":"44","author":"Kurtz","year":"2010","journal-title":"J Clin Gastroenterol"},{"issue":"8101","key":"10.1016\/j.gtc.2026.05.007_bib44","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S0140-6736(78)92151-7","article-title":"Diarrhea and pseudomembraneous colitis after gastrointestinal operations. A prospective study","volume":"312","author":"Keighley","year":"1978","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.gtc.2026.05.007_bib45","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S1473-3099(08)70233-0","article-title":"Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review","volume":"8","author":"Planche","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.007_bib46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/MCG.0000000000000769","article-title":"Outcomes with fidaxomicin therapy in Clostridium difficile infection","volume":"52","author":"Spiceland","year":"2018","journal-title":"J Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib47","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.007_bib48","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.jiac.2022.08.008","article-title":"Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: a systematic review and meta-analysis of randomized controlled trials","volume":"28","author":"Tashiro","year":"2022","journal-title":"J Infect Chemother"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib49","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.007_bib50","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1086\/430311","article-title":"Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole","volume":"40","author":"Musher","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.007_bib51","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1086\/430315","article-title":"Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada","volume":"40","author":"P\u00e9pin","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.007_bib52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/cid\/ciu313","article-title":"Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials","volume":"59","author":"Johnson","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"8358","key":"10.1016\/j.gtc.2026.05.007_bib53","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(83)91036-X","article-title":"Prospective randomised trial of metronidazole versus vancomycin for clostridium-difficile-associated diarrhoea and colitis","volume":"322","author":"Teasley","year":"1983","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.007_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0002-9343(89)90223-4","article-title":"Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens","volume":"86","author":"Fekety","year":"1989","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.gtc.2026.05.007_bib55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1086\/649016","article-title":"Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection","volume":"31","author":"Sethi","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.007_bib56","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ajg.2013.59","article-title":"Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis","volume":"108","author":"Kassam","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gtc.2026.05.007_bib57","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jama.2015.18098","article-title":"Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.gtc.2026.05.007_bib58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.7326\/M16-0271","article-title":"Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection a randomized trial","volume":"165","author":"Kelly","year":"2016","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.gtc.2026.05.007_bib60","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/ajg.2016.417","article-title":"Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections","volume":"111","author":"Carignan","year":"2016","journal-title":"Am J Gastroenterol"},{"issue":"15","key":"10.1016\/j.gtc.2026.05.007_bib61","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","article-title":"Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection","volume":"82","author":"Khanna","year":"2022","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.007_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.gtc.2026.05.007_bib63","doi-asserted-by":"crossref","first-page":"5054","DOI":"10.1128\/AAC.02606-13","article-title":"Antibiotics for treatment of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease","volume":"58","author":"Horton","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"10.1016\/j.gtc.2026.05.007_bib64","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.14309\/ajg.0000000000000460","article-title":"Long-duration oral vancomycin to treat clostridioides difficile in patients with inflammatory bowel disease is associated with a low rate of recurrence","volume":"114","author":"Lei","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.gtc.2026.05.007_bib65","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10096-018-3344-1","article-title":"Fidaxomicin for the treatment of clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)","volume":"37","author":"Vehreschild","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"10.1016\/j.gtc.2026.05.007_bib66","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1093\/jac\/dky368","article-title":"Pharmacokinetics and safety of fidaxomicin in patients with inflammatory bowel disease and Clostridium difficile infection: an open-label phase IIIb\/IV study (PROFILE)","volume":"73","author":"H\u00f6genauer","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaf056","article-title":"Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study","volume":"19","author":"Noviello","year":"2025","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.gtc.2026.05.007_bib68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/MCG.0000000000001633","article-title":"Outcomes of fecal microbiota transplantation for C. difficile infection in inflammatory bowel disease: a systematic review and meta-analysis","volume":"57","author":"Tariq","year":"2023","journal-title":"J Clin Gastroenterol"},{"issue":"9","key":"10.1016\/j.gtc.2026.05.007_bib69","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/ibd\/izaa283","article-title":"Inflammatory bowel disease outcomes following fecal microbiota transplantation for recurrent C. difficile infection","volume":"27","author":"Allegretti","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.gtc.2026.05.007_bib70","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1053\/j.gastro.2020.07.045","article-title":"Outcomes of fecal microbiota transplantation in patients with inflammatory bowel diseases and recurrent Clostridioides difficile infection","volume":"159","author":"Allegretti","year":"2020","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.gtc.2026.05.007_bib71","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/ibd\/izae291","article-title":"Safety and efficacy of fecal microbiota, live-jslm (REBYOTA\u00ae), for the prevention of recurrent Clostridioides difficile infection in participants with inflammatory bowel disease in PUNCH CD3-OLS","volume":"31","author":"Allegretti","year":"2025","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.gtc.2026.05.007_bib72","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/ibd.21514","article-title":"Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics\/immunomodulators?","volume":"17","author":"Yanai","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"10.1016\/j.gtc.2026.05.007_bib73","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ibd\/izy308","article-title":"Escalation of immunosuppressive therapy for inflammatory bowel disease is not associated with adverse outcomes after infection with Clostridium difficile","volume":"25","author":"Lukin","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"9","key":"10.1016\/j.gtc.2026.05.007_bib74","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1038\/ajg.2010.142","article-title":"Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease","volume":"105","author":"Das","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.gtc.2026.05.007_bib75","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.cgh.2009.05.031","article-title":"Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection","volume":"7","author":"Ben-Horin","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.gtc.2026.05.007_bib76","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.00946-23","article-title":"Fecal calprotectin level is nonlinearly associated with GI pathogen detection in patients with and without inflammatorybowel disease","volume":"61","author":"Newman","year":"2023","journal-title":"J Clin Microbiol"}],"container-title":["Gastroenterology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985532600035X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985532600035X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:30:50Z","timestamp":1786977050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985532600035X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S088985532600035X"],"URL":"https:\/\/doi.org\/10.1016\/j.gtc.2026.05.007","relation":{},"ISSN":["0889-8553"],"issn-type":[{"value":"0889-8553","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Clostridioides difficile Infection in Patients with Inflammatory Bowel Disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gtc.2026.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}